BlackThorn: BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders

(marketscreener.com) - First patient dosed in Phase 2 proof-of-concept trial of BTRX-140 in patients with major depressive disorder -https://www.marketscreener.com/news/BlackThorn-Therapeutics-Advances-Phase-2-Clinical-Development-for-Selective-KOR-Antagonist-BTRX-140--29880545/?utm_medium=RSS&utm_content=20200123